FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292590347> ?p ?o ?g. }

• W4292590347 endingPage "856" @default.
• W4292590347 startingPage "843" @default.
• W4292590347 abstract "Abstract Aims Low-grade inflammation couples dysmetabolic states to insulin resistance and atherosclerotic cardiovascular (CV) disease (ASCVD). Selective sodium–glucose co-transporter 2 (SGLT-2) inhibition by empagliflozin improves clinical outcomes in patients with ASCVD independently of its glucose lowering effects. Yet, its mechanism of action remains largely undetermined. Here, we aimed to test whether empagliflozin affects arterial thrombus formation in baseline (BSL) conditions or low-grade inflammatory states, a systemic milieu shared among patients with ASCVD. Methods and results Sixteen-week-old C57BL/6 mice were randomly assigned to acute administration of empagliflozin (25 mg/kg body weight) or vehicle, of which a subgroup was pre-treated biweekly over 4 weeks with super-low-dose lipopolysaccharide (LPS; 5 ng/kg body weight), before carotid thrombosis was induced by photochemical injury. The between-group difference in Doppler-flow probe detected time-to-occlusion remained within the predefined equivalence margin (Δ = |10.50|), irrespective of low-grade inflammation (95% confidence interval, –9.82 to 8.85 and –9.20 to 9.69), while glucose dropped by 1.64 and 4.84 mmoL/L, respectively. Ex vivo platelet aggregometry suggested similar activation status, corroborated by unchanged circulating platelet-factor 4 plasma levels. In concert, carotid PAI-1 expression and tissue factor (TF) activity remained unaltered upon SGLT-2 inhibition, and no difference in plasma D-dimer levels was detected, suggesting comparable coagulation cascade activation and fibrinolytic activity. In human aortic endothelial cells pre-treated with LPS, empagliflozin neither changed TF activity nor PAI-1 expression. Accordingly, among patients with established ASCVD or at high CV risk randomized to a daily dose of 10 mg empagliflozin signatures of thrombotic (i.e. TF) and fibrinolytic activity (i.e. PAI-1) remained unchanged, while plasma glucose declined significantly during 3 months of follow-up. Conclusion SGLT-2 inhibition by empagliflozin does not impact experimental arterial thrombus formation, neither under BSL conditions nor during sustained low-grade inflammation, and has no impact on proxies of thrombotic/fibrinolytic activity in patients with ASCVD. The beneficial pleiotropic effects of empagliflozin are likely independent of pathways mediating arterial thrombosis." @default.
• W4292590347 created "2022-08-22" @default.
• W4292590347 creator A5004358769 @default.
• W4292590347 creator A5004870743 @default.
• W4292590347 creator A5007434816 @default.
• W4292590347 creator A5019976194 @default.
• W4292590347 creator A5024812334 @default.
• W4292590347 creator A5036980579 @default.
• W4292590347 creator A5041969518 @default.
• W4292590347 creator A5045293936 @default.
• W4292590347 creator A5050799541 @default.
• W4292590347 creator A5053081441 @default.
• W4292590347 creator A5055832234 @default.
• W4292590347 creator A5067387423 @default.
• W4292590347 creator A5070952146 @default.
• W4292590347 creator A5077886543 @default.
• W4292590347 creator A5078666970 @default.
• W4292590347 date "2022-08-22" @default.
• W4292590347 modified "2023-10-06" @default.
• W4292590347 title "SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation" @default.
• W4292590347 cites W1971529415 @default.
• W4292590347 cites W1988371749 @default.
• W4292590347 cites W1992113107 @default.
• W4292590347 cites W1998442981 @default.
• W4292590347 cites W2018213438 @default.
• W4292590347 cites W2083592407 @default.
• W4292590347 cites W2085507409 @default.
• W4292590347 cites W2092785862 @default.
• W4292590347 cites W2094461882 @default.
• W4292590347 cites W2113507924 @default.
• W4292590347 cites W2129917444 @default.
• W4292590347 cites W2130585857 @default.
• W4292590347 cites W2131536322 @default.
• W4292590347 cites W2133010654 @default.
• W4292590347 cites W2134738156 @default.
• W4292590347 cites W2141015143 @default.
• W4292590347 cites W2146933358 @default.
• W4292590347 cites W2151582570 @default.
• W4292590347 cites W2166035232 @default.
• W4292590347 cites W2210931878 @default.
• W4292590347 cites W2313542015 @default.
• W4292590347 cites W2549669347 @default.
• W4292590347 cites W2604277961 @default.
• W4292590347 cites W2626446274 @default.
• W4292590347 cites W2767338841 @default.
• W4292590347 cites W2791313650 @default.
• W4292590347 cites W2796184292 @default.
• W4292590347 cites W2805430758 @default.
• W4292590347 cites W2883163580 @default.
• W4292590347 cites W2887940657 @default.
• W4292590347 cites W2899984884 @default.
• W4292590347 cites W2900413769 @default.
• W4292590347 cites W2903431537 @default.
• W4292590347 cites W2905043812 @default.
• W4292590347 cites W2907012814 @default.
• W4292590347 cites W2987567839 @default.
• W4292590347 cites W3004876731 @default.
• W4292590347 cites W3024144838 @default.
• W4292590347 cites W3043378534 @default.
• W4292590347 cites W3044871294 @default.
• W4292590347 cites W3046854283 @default.
• W4292590347 cites W3081830235 @default.
• W4292590347 cites W3087532991 @default.
• W4292590347 cites W3091950876 @default.
• W4292590347 cites W3107307985 @default.
• W4292590347 cites W3112392549 @default.
• W4292590347 cites W3155824129 @default.
• W4292590347 cites W3184273258 @default.
• W4292590347 cites W45316589 @default.
• W4292590347 doi "https://doi.org/10.1093/cvr/cvac126" @default.
• W4292590347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35993135" @default.
• W4292590347 hasPublicationYear "2022" @default.
• W4292590347 type Work @default.
• W4292590347 citedByCount "2" @default.
• W4292590347 countsByYear W42925903472023 @default.
• W4292590347 crossrefType "journal-article" @default.
• W4292590347 hasAuthorship W4292590347A5004358769 @default.
• W4292590347 hasAuthorship W4292590347A5004870743 @default.
• W4292590347 hasAuthorship W4292590347A5007434816 @default.
• W4292590347 hasAuthorship W4292590347A5019976194 @default.
• W4292590347 hasAuthorship W4292590347A5024812334 @default.
• W4292590347 hasAuthorship W4292590347A5036980579 @default.
• W4292590347 hasAuthorship W4292590347A5041969518 @default.
• W4292590347 hasAuthorship W4292590347A5045293936 @default.
• W4292590347 hasAuthorship W4292590347A5050799541 @default.
• W4292590347 hasAuthorship W4292590347A5053081441 @default.
• W4292590347 hasAuthorship W4292590347A5055832234 @default.
• W4292590347 hasAuthorship W4292590347A5067387423 @default.
• W4292590347 hasAuthorship W4292590347A5070952146 @default.
• W4292590347 hasAuthorship W4292590347A5077886543 @default.
• W4292590347 hasAuthorship W4292590347A5078666970 @default.
• W4292590347 hasConcept C126322002 @default.
• W4292590347 hasConcept C134018914 @default.
• W4292590347 hasConcept C164705383 @default.
• W4292590347 hasConcept C2775887513 @default.
• W4292590347 hasConcept C2776246508 @default.
• W4292590347 hasConcept C2776914184 @default.
• W4292590347 hasConcept C2777180221 @default.

• next